MRBL Enhanced Equity ETF (EDGE) Dividend History

Company News

• PDSB Loss Improves as Costs Drop

  PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.

  The Motley Fool

  Featured Companies: PDSB